BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment

BridgeBio Oncology Therapeutics remains a Buy, despite a >30% decline since prior coverage, supported by three promising KRAS/RAS-targeted drug candidates. BBOT's lead asset, BB-8520, showed a 65% objective response rate and 100% disease control in KRAS G12C NSCLC, exceeding results from approved competitors. Further mature data readouts for BBOT’s pipeline are expected in 2H26, representing key catalysts for share price re-rating and future funding opportunities. BBOT maintains robust funding into 2028 and has strengthened its management team with experienced oncology leaders, positioning well for upcoming clinical milestones.